日本造血・免疫細胞療法学会雑誌
Online ISSN : 2436-455X
短報
COVID-19発症後に4ヶ月以上SARS-CoV-2の持続排出を認めた同種造血幹細胞移植患者
宮崎 幸大末盛 浩一郎桑原 希谷口 裕美村上 忍小西 達矢名部 彰悟丸田 雅樹越智 俊元谷本 一史宮本 仁志山之内 純岩城 洋己四宮 博人竹中 克斗
著者情報
ジャーナル フリー

2023 年 12 巻 2 号 p. 129-132

詳細
抄録

 The duration of infectivity associated with severe acute respiratory coronavirus-2 (SARS-CoV-2) is generally approximately 10 days from the onset of symptoms. However, some studies have reported that this period may be longer than 20 days in patients with allogeneic hematopoietic stem cell transplantation (HSCT). Herein, we report a case of persistent viral SARS-CoV-2 shedding for 126 days in an individual with HSCT. When the patient was infected with coronavirus disease 2019 (COVID-19), tacrolimus and prednisolone were administered for graft versus host disease. The viral load, which was monitored regularly by quantitative antigen testing, decreased with the administration of antiviral agents but re-elevated rapidly after discontinuation. Tapering of tacrolimus and prednisolone resulted in a gradual reduction of the viral load and its eventual disappearance. This case report highlights the importance of determining persistent infectivity in patients with allogeneic HSCT using viral testing prior to release from isolation.

Fullsize Image
著者関連情報
© 2023 一般社団法人日本造血・免疫細胞療法学会
前の記事
feedback
Top